Form 4: Tyra Biosciences Director Sells Over 50,000 Shares in Open Market Transactions

Gilla Kaplan, a Director at Tyra Biosciences, Inc. (TYRA), has reported the sale of 51,814 shares of common stock over three separate transactions in mid-June 2025.

Summary

• Gilla Kaplan, a Director of Tyra Biosciences, Inc. (TYRA), sold a total of 51,814 shares of common stock in open market transactions.
• On June 12, 2025, 30,000 shares were sold at a weighted average price of $10.3085 per share, with prices ranging from $10.25 to $10.51.
• On June 13, 2025, an additional 15,000 shares were sold at a weighted average price of $10.3055 per share, with prices ranging from $10.25 to $10.43.
• On June 16, 2025, 6,814 shares were sold at a weighted average price of $10.3795 per share, with prices ranging from $10.35 to $10.46.
• Following these transactions, Gilla Kaplan beneficially owns 37,809 shares of Tyra Biosciences common stock directly.

Sentiment

Score: 3

Explanation: The sentiment is moderately negative due to a director selling a substantial number of shares, which can be interpreted as a lack of confidence, despite being a routine disclosure.

Negatives

• The sale of a significant number of shares by a director could be interpreted by investors as a lack of confidence in the company's near-term prospects or future growth.

Risks

• Potential negative market perception and investor sentiment due to insider selling.
• Increased selling pressure on the stock if other insiders follow suit or if the market interprets these sales as a bearish signal.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider trading disclosures, such as this Form 4, are standard regulatory filings that provide transparency into the buying and selling activities of a company's directors and officers. In the biotechnology industry, insider sales can occur for various personal financial planning reasons, but significant sales are often scrutinized by investors for potential insights into management's view of the company's prospects.

Comparison to Industry Standards

• While direct comparisons to specific company projects or financial results are not applicable for an insider trading report, the sale of shares by a director is generally viewed by the market as a neutral to slightly negative signal. In the biotech sector, such sales are common for personal liquidity, but significant or widespread insider selling across multiple executives could be perceived less favorably than in companies where insiders are accumulating shares, which often signals strong confidence.

Stakeholder Impact

• Shareholders may interpret the director's share sales as a negative signal, potentially leading to decreased investor confidence or selling pressure on the stock.

Key Dates

Recommendation

Keywords

Tyra Biosciences, TYRA, Form 4, Insider Trading, Stock Sale, Director, Gilla Kaplan, Biotechnology